21. (amended) A method of inhibiting the growth of a tumor in an animal comprising administering to said animal an effective amount of a pharmaceutical composition comprising an oligonucleotide from 8 to 30 nucleotides connected by covalent linkages and a pharmaceutically acceptable carrier, and wherein said oligonucleotide has a sequence specifically hybridizable with a nucleic acid molecule encoding human JNK2 protein and said oligonucleotide inhibits growth of said tumor in said animal.

22. (amended) The method of claim 21 wherein said pharmaceutical composition further comprises one or more compounds, wherein said compounds include a stabilizing agent, a penetration enhancer, and a chemotherapeutic agent.

28. (amended) A method of treating an animal having a disease or condition associated with a human JNK2 protein comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide from 8 to 30 nucleotides connected by covalent linkages and a pharmaceutically acceptable carrier, wherein said oligonucleotide has a sequence specifically hybridizable with a nucleic acid molecule encoding human JNK2 protein, so that expression of the human JNK2 protein is inhibited.

Please add the following new claims:

-34. The method of claim 33 wherein the cancer is prostate cancer.

35. The method of claim 28 wherein the oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41.

36. The method of claim 28 wherein the oligonucleotide comprises SEQ ID NO: 31.

37. The method of claim 21 wherein the oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41.

38. The method of claim 21 wherein the oligonucleotide comprises SEQ ID NO: 31.

39. The method of claim 14 wherein the oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41.